Nucleic acids encoding engineered imine reductases
US-10308966-B2 · Jun 4, 2019 · US
Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
US10787689B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10787689-B2 |
| Application number | US-201916655547-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 17, 2019 |
| Priority date | May 11, 2012 |
| Publication date | Sep 29, 2020 |
| Grant date | Sep 29, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. An engineered polypeptide having imine reductase activity, wherein said polypeptide has at least 90% sequence identity to SEQ ID NO:2, and comprises a substitution at a position corresponding to position 156 of SEQ ID NO:2, wherein the amino acid at position 156 has been replaced with a non-polar, aliphatic, or polar residue. 2. The engineered polypeptide having imine reductase activity of claim 1 , wherein said polypeptide has at least 90% sequence identity to SEQ ID NO:2, wherein the amino acid at the position corresponding to position 156 of SEQ ID NO:2 has been replaced with threonine. 3. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1a) pyruvate, and substrate compound (2b) butylamine to product compound (3b), N-2-(butylamino)propanoic acid, under suitable reaction conditions. 4. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2a) L-norvaline to product compound (3c), (S)-2-(cyclohexylamino)pentanoic acid, under suitable reaction conditions. 5. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2b) butylamine to product compound (3d), N-butylcyclohexanamine, under suitable reaction conditions. 6. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1i), and substrate compound (2b) to product compound (3n), under suitable reaction conditions. 7. The engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1j), and substrate compound (2b) to product compound (3o), under suitable reaction conditions.
Assignees
Inventors
Classifications
- C12N9/0028Primary
with NAD or NADP as acceptor (1.5.1) · CPC title
Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms (ergot-alcaloids C12P17/183) · CPC title
containing a six-membered hetero ring · CPC title
Tauropine dehydrogenase (1.5.1.23) · CPC title
Opine dehydrogenase (1.5.1.28) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10787689B2 cover?
- The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/0028. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).